Company logo

NGM - NGM Biopharmaceuticals, Inc.

NASDAQ -> Healthcare -> Biotechnology
South San Francisco, United States
Type: Equity

NGM price evolution
NGM
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Current assets
Cash $61.27 $56.93 $57.23 $71.5
Short term investments $88.37 $114.57 $140.27 $163.46
Net receivables $0.06 $0.74 $1.26
Inventory
Total current assets $156.44 $177.04 $204.4 $242.53
Long term investments
Property, plant & equipment $7.03 $7.82 $8.83 $9.55
Goodwill & intangible assets
Total noncurrent assets $12.42 $15.11 $16.14 $16.31
Total investments $88.37 $114.57 $140.27 $163.46
Total assets $168.87 $192.15 $220.54 $258.84
Current liabilities
Accounts payable $2.98 $4.69 $5.86 $13.29
Deferred revenue $0.11 $0.69 $0.38
Short long term debt $1.38 $2.75 $4.07
Total current liabilities $20.08 $22.34 $28.42 $37.9
Long term debt
Total noncurrent liabilities $0.15
Total debt $1.38 $2.75 $4.07
Total liabilities $20.23 $22.34 $28.42 $37.9
Shareholders' equity
Retained earnings -$724.01 -$696.34 -$667.54 -$629.28
Other shareholder equity $0.02 -$0.08 -$0.15 -$0.1
Total shareholder equity $148.64 $169.81 $192.12 $220.93
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $61.27 $77.41 $153.29 $148.52
Short term investments $88.37 $198.04 $214.46 $148.14
Net receivables $0.06 $7.58 $4.95 $0.33
Inventory
Total current assets $156.44 $288.86 $379.28 $308.43
Long term investments
Property, plant & equipment $7.03 $10.59 $14.12 $14.53
Goodwill & intangible assets
Total noncurrent assets $12.42 $18.54 $23.11 $20.62
Total investments $88.37 $198.04 $214.46 $148.14
Total assets $168.87 $307.4 $402.39 $329.04
Current liabilities
Accounts payable $2.98 $8.45 $5.25 $9.66
Deferred revenue $0.37 $17.77 $2.98
Short long term debt $5.38 $5.08
Total current liabilities $20.08 $47.84 $61.35 $42.58
Long term debt $5.38
Total noncurrent liabilities $0.15 $5.38 $6.42
Total debt $5.38 $10.46
Total liabilities $20.23 $47.84 $66.74 $49
Shareholders' equity
Retained earnings -$724.01 -$581.63 -$418.97 -$298.63
Other shareholder equity $0.02 -$0.3 -$0.13 $0
Total shareholder equity $148.64 $259.56 $335.65 $280.04
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $21.89 $22.94 $32.35 $40.86
Selling, general & administrative $7.94 $8.67 $9.65 $11.58
Total operating expenses $29.83 $31.61 $42 $52.44
Operating income -$29.83 -$31.61 -$42 -$52.44
Income from continuing operations
EBIT -$27.67 -$28.8 -$38.26 -$47.65
Income tax expense
Interest expense
Net income
Net income -$27.67 -$28.8 -$38.26 -$47.65
Income (for common shares) -$27.67 -$28.8 -$38.26 -$47.65
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $118.04 $181.07 $161.71 $163.97
Selling, general & administrative $37.84 $40.52 $36.87 $27.23
Total operating expenses $155.88 $221.58 $198.58 $191.2
Operating income -$155.88 -$221.58 -$198.58 -$191.2
Income from continuing operations
EBIT -$142.38 -$162.67 -$120.33 -$102.49
Income tax expense
Interest expense
Net income
Net income -$142.38 -$162.67 -$120.33 -$102.49
Income (for common shares) -$142.38 -$162.67 -$120.33 -$102.49
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Net income -$27.67 -$28.8 -$38.26 -$47.65
Operating activities
Depreciation $1.06 $1.06 $1.08 $1.12
Business acquisitions & disposals
Stock-based compensation $6.3 $6.41 $7.48 $8.54
Total cash flows from operations -$22.96 -$27.16 -$40.25 -$41.83
Investing activities
Capital expenditures -$0.19 -$0.29 -$0.1 -$0.67
Investments $27.38 $27.16 $24.69 $36.31
Total cash flows from investing $27.19 $26.87 $24.59 $35.64
Financing activities
Dividends paid
Sale and purchase of stock $0.11 $1.39 $0.28
Net borrowings
Total cash flows from financing $0.11 $1.39 $0.28
Effect of exchange rate
Change in cash and equivalents $4.34 -$0.29 -$14.28 -$5.91
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$142.38 -$162.67 -$120.33 -$102.49
Operating activities
Depreciation $4.32 $5.98 $7.9 $6.55
Business acquisitions & disposals
Stock-based compensation $28.72 $32.38 $26.24 $15.65
Total cash flows from operations -$132.2 -$144.44 -$73.23 -$83.5
Investing activities
Capital expenditures -$1.25 -$1.86 -$1.68 -$1.88
Investments $115.54 $16.18 -$69.97 -$49.12
Total cash flows from investing $114.29 $14.32 -$71.65 -$51
Financing activities
Dividends paid
Sale and purchase of stock $1.77 $54.23 $149.66 $36.15
Net borrowings
Total cash flows from financing $1.77 $54.23 $149.66 $35.54
Effect of exchange rate
Change in cash and equivalents -$16.14 -$75.88 $4.78 -$98.96
Fundamentals
Market cap $127.68M
Enterprise value $66.41M
Shares outstanding 82.91M
Revenue $0.00
EBITDA -$138.06M
EBIT -$142.38M
Net Income -$142.38M
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio -0.90
EV/Sales N/A
EV/EBITDA -0.48
EV/EBIT -0.47
P/S ratio N/A
P/B ratio 0.86
Book/Share 1.79
Cash/Share 0.74
EPS -$1.72
ROA -67.77%
ROE -77.85%
Debt/Equity 0.14
Net debt/EBITDA 0.30
Current ratio 7.79
Quick ratio 7.79